Carfilzomib produced significant clinical benefit in multiple myeloma

Share this article:

A study involving 30 cancer centers in the United States and Canada yielded durable responses to and an acceptable tolerability profile for carfilzomib (Kyprolis), which was approved last month by the FDA for the treatment of advanced multiple myeloma. The results of this trial were published online ahead of print by the journal Blood a few days later.

In the open-label, single-arm, phase 2b study, a team led by David S. Siegel, MD, PhD, chief of multiple myeloma at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey, evaluated this next-generation, selective proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Carfilzomib 20 mg/m2 was administered intravenously twice weekly for 3 of 4 weeks, and then in doses of 27 mg/m2 for up to 12 cycles.

The 266 evaluable patients had received at least two prior therapies, including bortezomib, lenalidomide, and thalidomide. Most patients (95%) had not responded to their last therapy, and 80% were refractory to or intolerant of both bortezomib and lenalidomide.

With carfilzomib, overall response rate was 23.7%, with a median duration of response of 7.8 months and a median overall survival of 15.6 months. Adverse events were manageable without cumulative toxicities; common adverse events were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%). A total of 33 patients (12.4%) experienced peripheral neuropathy, primarily grades 1 and 2, and the same number of patients withdrew from the study due to an adverse event.

The researchers concluded that durable responses and the acceptable tolerability profile in this heavily pretreated population demonstrated the potential of carfilzomib to offer meaningful clinical benefit, particularly given the limited number of treatment options available to persons with advanced-stage multiple myeloma and the diminished prospects for retreatment once a therapy has been used.

.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Rehabilitation benefits advanced cancer patients

Patients with advanced cancer can benefit from a rehabilitation program combining exercise, nutritional counselling, and symptom control, according to an evidence review.

Exposure to dim light at night may lead to tamoxifen resistance in ...

For rats bearing human breast tumors, exposure to dim light at night made the tumors resistant to the breast cancer drug tamoxifen, according to recently published data.

Combined treatment approach for locally advanced pancreatic cancer aims to identify biomarkers

Investigators are developing a novel, multistep investigational treatment for locally advanced pancreatic cancer, which is complex and difficult to treat.